|
|
 | | | |
- close
- close
- close
- close
Nektar Therapeutics (NKTR) |
Benzinga
Apr 16
Comment
Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of...
TheStreet.com
Feb 22
Comment
WINDERMERE, Fla. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.
Stocks that are making large moves like these are favorites among short-term traders...
StreetInsider.com
Feb 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Nektar+%28NKTR%29+Commences+Etirinotecan+Pegol+Phase+2+in+NSCLC+Patients/8058992.html for the full story.
Benzinga
Nov 13
Comment
In a report published Tuesday, Bank of America lowered its price objective on Nektar Therapeutics (NASDAQ: NKTR) from $7.50 to $7.00 and maintained its Underperform rating.
Bank of America noted, "following top line ph 3 results for naloxegol...
Benzinga
Nov 12
Comment
Shares of Nektar Therapeutics (NASDAQ: NKTR) have plunged on Monday after the FDA raised concerns that a class of opioid constipation medications may cause heart problems. The company said that the FDA's heart-safety concerns could cast new risks...
FierceBiotech
Nov 12
Comment
Breaking from a long string of trial failures, AstraZeneca ($AZN) offered up positive data from a pair of late-stage Phase III study of naloxegol, an experimental drug for opioid-induced constipation in-licensed from Nektar ($NKTR) in a $1.5...
StreetInsider.com
Nov 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Nektar+Therapeutics+%28NKTR%29+Tops+Q3+EPS+by+1c/7863595.html for the full story.
StreetInsider.com
Oct 15
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Nektar+Therapeutics+%28NKTR%29+Reports+Publication+of+Encouraging+NKTR-171+Data+on+Neuropathic+Pain/7791863.html for the full story.
Benzinga
Sep 27
Comment
Nektar Therapeutics (NASDAQ: NKTR) shares jumped 1.52% to create a new 52-week high of $10.69. Nektar Therapeutics shares have jumped 111.45% over the past 52 weeks, while the S&P 500 index has gained 23.52% in the same period.
PDF Solutions...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
